News Releases

November 14, 2017 at 4:01 PM EST

Summary Toggle Molecular Templates, Inc. Reports Third Quarter 2017 Financial Results

Completed Merger with Threshold Pharmaceuticals in August Recent Equity Financings of $60 Million Provide Cash Runway into late 2019 MT-3724 Advancing in Clinical Trials with New Data Expected in 1H18 AUSTIN, Texas , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.
October 24, 2017 at 8:52 AM EDT

Summary Toggle Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)

- Maximum Tolerated Dose of MT-3724 Identified AUSTIN, Texas , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), today announced the dosing of the first
October 6, 2017 at 8:00 AM EDT

Summary Toggle Molecular Templates to Present at the 2017 BIO Investor Forum

AUSTIN, Texas , Oct. 06, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
September 22, 2017 at 1:54 PM EDT

Summary Toggle Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences

AUSTIN, Texas , Sept. 22, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
September 6, 2017 at 2:17 PM EDT

Summary Toggle Molecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference

AUSTIN, Texas , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
August 30, 2017 at 8:30 AM EDT

Summary Toggle Molecular Templates to Ring NASDAQ Closing Bell
August 14, 2017 at 8:00 AM EDT

Summary Toggle Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference

AUSTIN, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM ) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in
August 3, 2017 at 9:00 AM EDT

Summary Toggle Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next-Generation Oncology Therapies

OSAKA, Japan & AUSTIN, Texas--( BUSINESS WIRE )--Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs. The collaboration will apply Molecular Templates’ engineered toxin bodies (ETB)
August 2, 2017 at 12:00 AM EDT

Summary Toggle Molecular Templates Completes Merger with Threshold Pharmaceuticals and Private Placements

Combined Company Has a Unique Biological Platform with a Differentiated Mechanism of Action in Oncology and Two Clinical-Stage Candidates, MT-3724 and Evofosfamide Combined Company to Commence Trading on The Nasdaq Capital Market on August 2, 2017 under Ticker Symbol “MTEM” Approximately $75.0
March 30, 2017 at 9:24 AM EDT

Summary Toggle Molecular Templates Announces Presentations Featuring Engineered Toxin Bodies at the 2017 American Association for Cancer Research (AACR) Annual Meeting

News Releases

News Releases

About Molecular Templates

Recent Posts